Genome Editing in Cardiovascular Diseases

Overview

Journal Nat Rev Cardiol

Specialty Cardiology & Vascular Diseases

Date 2016 Sep 10

PMID 27609628

Citations 47

Authors

Alanna Strong

Kiran Musunuru

Affiliations

Soon will be listed here.

Abstract

Genome-editing tools, which include zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 (Cas9) systems, have emerged as an invaluable technology to achieve somatic and germline genomic manipulation in cells and model organisms for multiple applications, including the creation of knockout alleles, introducing desired mutations into genomic DNA, and inserting novel transgenes. Genome editing is being rapidly adopted into all fields of biomedical research, including the cardiovascular field, where it has facilitated a greater understanding of lipid metabolism, electrophysiology, cardiomyopathies, and other cardiovascular disorders, has helped to create a wider variety of cellular and animal models, and has opened the door to a new class of therapies. In this Review, we discuss the applications of genome-editing technology throughout cardiovascular disease research and the prospect of in vivo genome-editing therapies in the future. We also describe some of the existing limitations of genome-editing tools that will need to be addressed if cardiovascular genome editing is to achieve its full scientific and therapeutic potential.

Citing Articles

Rapid Detection of Fusions in Acute Promyelocytic Leukemia: CRISPR/Cas9 Nanopore Sequencing with Adaptive Sampling.

Middlezong W, Stinnett V, Phan M, Phan B, Morsberger L, Klausner M Biomolecules. 2025; 14(12.

PMID: 39766302 PMC: 11674480. DOI: 10.3390/biom14121595.

Cardiomyopathy: pathogenesis and therapeutic interventions.

Huang S, Li J, Li Q, Wang Q, Zhou X, Chen J MedComm (2020). 2024; 5(11):e772.

PMID: 39465141 PMC: 11502724. DOI: 10.1002/mco2.772.

Application and perspective of CRISPR/Cas9 genome editing technology in human diseases modeling and gene therapy.

Zhang M, Li H, Jin Y Front Genet. 2024; 15:1364742.

PMID: 38666293 PMC: 11043577. DOI: 10.3389/fgene.2024.1364742.

Current Landscape of Gene Therapy for the Treatment of Cardiovascular Disorders.

Wal P, Aziz N, Singh C, Rasheed A, Tyagi L, Agrawal A Curr Gene Ther. 2024; 24(5):356-376.

PMID: 38288826 DOI: 10.2174/0115665232268840231222035423.

Innovative Strategies of Reprogramming Immune System Cells by Targeting CRISPR/Cas9-Based Genome-Editing Tools: A New Era of Cancer Management.

Allemailem K, Alsahli M, Almatroudi A, Alrumaihi F, Al Abdulmonem W, Moawad A Int J Nanomedicine. 2023; 18:5531-5559.

PMID: 37795042 PMC: 10547015. DOI: 10.2147/IJN.S424872.

References

Coelho T, Adams D, Silva A, Lozeron P, Hawkins P, Mant T . Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013; 369(9):819-29. DOI: 10.1056/NEJMoa1208760. View

Lepperhof V, Polchynski O, Kruttwig K, Bruggemann C, Neef K, Drey F . Bioluminescent imaging of genetically selected induced pluripotent stem cell-derived cardiomyocytes after transplantation into infarcted heart of syngeneic recipients. PLoS One. 2014; 9(9):e107363. PMC: 4167328. DOI: 10.1371/journal.pone.0107363. View

Zhang M, DAniello C, Verkerk A, Wrobel E, Frank S, Ward-van Oostwaard D . Recessive cardiac phenotypes in induced pluripotent stem cell models of Jervell and Lange-Nielsen syndrome: disease mechanisms and pharmacological rescue. Proc Natl Acad Sci U S A. 2014; 111(50):E5383-92. PMC: 4273331. DOI: 10.1073/pnas.1419553111. View

Orthwein A, Noordermeer S, Wilson M, Landry S, Enchev R, Sherker A . A mechanism for the suppression of homologous recombination in G1 cells. Nature. 2015; 528(7582):422-6. PMC: 4880051. DOI: 10.1038/nature16142. View

Branzei D, Foiani M . Regulation of DNA repair throughout the cell cycle. Nat Rev Mol Cell Biol. 2008; 9(4):297-308. DOI: 10.1038/nrm2351. View

Liang P, Xu Y, Zhang X, Ding C, Huang R, Zhang Z . CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes. Protein Cell. 2015; 6(5):363-372. PMC: 4417674. DOI: 10.1007/s13238-015-0153-5. View

Nelson C, Hakim C, Ousterout D, Thakore P, Moreb E, Castellanos Rivera R . In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science. 2016; 351(6271):403-7. PMC: 4883596. DOI: 10.1126/science.aad5143. View

Shen B, Zhang W, Zhang J, Zhou J, Wang J, Chen L . Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects. Nat Methods. 2014; 11(4):399-402. DOI: 10.1038/nmeth.2857. View

Hirano H, Gootenberg J, Horii T, Abudayyeh O, Kimura M, Hsu P . Structure and Engineering of Francisella novicida Cas9. Cell. 2016; 164(5):950-61. PMC: 4899972. DOI: 10.1016/j.cell.2016.01.039. View

10.

Wang Y, Liang P, Lan F, Wu H, Lisowski L, Gu M . Genome editing of isogenic human induced pluripotent stem cells recapitulates long QT phenotype for drug testing. J Am Coll Cardiol. 2014; 64(5):451-9. PMC: 4149735. DOI: 10.1016/j.jacc.2014.04.057. View

11.

Tebas P, Stein D, Tang W, Frank I, Wang S, Lee G . Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med. 2014; 370(10):901-10. PMC: 4084652. DOI: 10.1056/NEJMoa1300662. View

12.

Ran F, Hsu P, Lin C, Gootenberg J, Konermann S, Trevino A . Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell. 2013; 154(6):1380-9. PMC: 3856256. DOI: 10.1016/j.cell.2013.08.021. View

13.

Yu C, Liu Y, Ma T, Liu K, Xu S, Zhang Y . Small molecules enhance CRISPR genome editing in pluripotent stem cells. Cell Stem Cell. 2015; 16(2):142-7. PMC: 4461869. DOI: 10.1016/j.stem.2015.01.003. View

14.

Fu Y, Sander J, Reyon D, Cascio V, Joung J . Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat Biotechnol. 2014; 32(3):279-284. PMC: 3988262. DOI: 10.1038/nbt.2808. View

15.

Ding Q, Strong A, Patel K, Ng S, Gosis B, Regan S . Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing. Circ Res. 2014; 115(5):488-92. PMC: 4134749. DOI: 10.1161/CIRCRESAHA.115.304351. View

16.

Mali P, Aach J, Stranges P, Esvelt K, Moosburner M, Kosuri S . CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat Biotechnol. 2013; 31(9):833-8. PMC: 3818127. DOI: 10.1038/nbt.2675. View

17.

Cho S, Kim S, Kim J, Kim J . Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol. 2013; 31(3):230-2. DOI: 10.1038/nbt.2507. View

18.

Moreno C, Hoffman M, Stodola T, Didier D, Lazar J, Geurts A . Creation and characterization of a renin knockout rat. Hypertension. 2011; 57(3):614-9. PMC: 3513323. DOI: 10.1161/HYPERTENSIONAHA.110.163840. View

19.

Niu Y, Shen B, Cui Y, Chen Y, Wang J, Wang L . Generation of gene-modified cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos. Cell. 2014; 156(4):836-43. DOI: 10.1016/j.cell.2014.01.027. View

20.

Moscou M, Bogdanove A . A simple cipher governs DNA recognition by TAL effectors. Science. 2009; 326(5959):1501. DOI: 10.1126/science.1178817. View